drugset / Trial / NCT04979572

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

NCT04979572

Phase 1 Completed 41 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindBasic science

Summary

A Phase 1, Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Dose of TS-172 in Healthy Adult Subjects

Timeline

Start
2021-08-16
Primary completion
2022-01-26
Completion
2022-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 10 mg
Subject TS-172 Unknown 30 mg
Subject TS-172 Unknown 90 mg
Subject TS-172 Unknown 270 mg

Indications

No indication recorded.